Syn 2002

Drug Profile

Syn 2002

Alternative Names: Dox-SynB1; Dox-SynB3; Doxorubicin peptide conjugate - Synt:em; Syn2002; Vectorised doxorubicin - Synt:em

Latest Information Update: 20 Jan 2011

Price : $50

At a glance

  • Originator Synt:em
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors; Reactive oxygen species stimulants; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 20 Jan 2011 No development reported - Preclinical for Cancer in France (unspecified route)
  • 23 Jun 2004 Syn 2002 is available for licensing (http://www.syntem.com)
  • 10 Jul 2003 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top